IP Library › Granted Patent US 12,516,046

Granted Patent B2

US 12,516,046 · App. 18/009,306 · Granted Jan 6, 2026

2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors

Inventors: Ashok Arasappan (Bridgewater, NJ); Ian M. Bell (Harleysville, PA); Christopher James Bungard (Lansdale, PA); Christopher S. Burgey (Ambler, PA); Jason Michael Cox (Rancho Santa Fe, CA); Deodial Guy Guiadeen (Chesterfield, NJ); Michael J. Kelly, III (Paoli, PA); Mark E. Layton (Harleysville, PA); Hong Liu (Hillsborough, NJ); Jian Liu (Edison, NJ); James T. Olsen (Lansdale, PA); James J. Perkins (Churchville, PA); Jeffrey William Schubert (North Wales, PA); Akshay A. Shah (Robbinsville, NJ); Shawn J. Stachel (Perkasie, PA); Michael David VanHeyst (Harleysville, PA); Zhe Wu (Blue Bell, PA)

Assignee: Merck Sharp & Dohme LLC

C07D413/12 C07D263/24 C07D417/12

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,516,046
App. No.: 18/009,306
Granted: Jan 6, 2026
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Na v 1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Na v 1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

Claims (646)

1 . A compound of structural Formula I:

or a pharmaceutically acceptable salt thereof, wherein

one of A and B is selected from:

1) aryl, and

2) heteroaryl,

wherein aryl and heteroaryl are unsubstituted or substituted with one to five substituents selected from R a ,

and the other of A and B is selected from:

1) aryl

2) heteroaryl,

3) C 1-6 alkyl-aryl,

4) —C 3-8 cycloalkyl-aryl,

5) —C 2-8 cycloheteroalkyl-aryl,

6) —C 1-6 alkyl-heteroaryl,

7) —C 3-8 cycloalkyl-heteroaryl,

8) —C 2-8 cycloheteroalkyl-heteroaryl,

9) —C 1-6 alkyl-O-aryl,

10) —C 1-6 alkyl-O-heteroaryl,

11) C 3-12 cycloalkyl,

12) C 2-12 cycloheteroalkyl,

13) —C 1-6 alkyl-C 3-12 cycloalkyl,

14) —C 1-6 alkyl-C 2-12 cycloheteroalkyl,

15) —C 1-6 alkyl-O—C 3-12 cycloalkyl,

16) —C 1-6 alkyl-O—C 2-12 cycloheteroalkyl,

17) —C 0-6 alkyl-aryl fused to a C 4-6 cycloalkyl or C 4-6 cycloheteroalkyl containing 1-3 heteroatoms independently selected from O, S and N(R h ) 2 ,

18) —C 0-6 alkyl-aryl fused to a C 4-6 cycloalkenyl or C 4-6 cycloheteroalkenyl containing 1-3 heteroatoms independently selected from O, S and N(R h ) 2 ,

19) —C 0-6 alkyl-heteroaryl fused to C 4-6 cycloalkyl or C 4-6 cycloheteroalkyl containing 1-3 heteroatoms independently selected from O, S and N(R h ) 2 , and

20) —C 0-6 alkyl-heteroaryl fused to C 4-6 cycloalkenyl or C 4-6 cycloheteroalkenyl containing 1-3 heteroatoms independently selected from O, S and N(R h ) 2 ,

wherein alkyl, cycloalkyl, cycloheteroalkyl, cycloalkenyl, aryl and heteroaryl are unsubstituted or substituted with one to five substituents selected from R b ;

R 1 is selected from the group consisting of:

1) hydrogen,

2) —C 1-6 alkyl,

3) —C 3-6 alkenyl,

4) —C 3-6 alkynyl,

5) —C 3-10 cycloalkyl,

6) —C 2-10 cycloheteroalkyl,

7) —C 1-6 alkyl-O—C 1-6 alkyl-,

8) —(CH 2 ) S (O)R j ,

9) —(CH 2 ) S C(O)NR e R j ,

10) —(CH 2 ) n NR e C(O)R j ,

11) —(CH 2 ) n NR e C(O)OR j ,

12) —(CH 2 ) n NR e C(O)N(R e ) 2 ,

13) —(CH 2 ) n NR e C(O)NR e R j ,

14) —(CH 2 ) n NR e S(O) m R j ,

15) —(CH 2 ) n NR e S(O) m N(R e ) 2 ,

16) —(CH 2 ) n NR e S(O) m NR e R j , and

17) —(CH 2 ) n NR e R j ,

wherein each CH 2 , alkyl, alkenyl, alkynyl, cycloalkyl and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from R c ;

R 2 is selected from the group consisting of:

1) hydrogen,

2) —C 1-6 alkyl,

3) —C 2-6 alkenyl,

4) —C 2-6 alkynyl,

5) —C 3-10 cycloalkyl,

6) —C 2-10 cycloheteroalkyl,

7) —C 1-6 alkyl-O—C 1-6 alkyl-,

8) —(CH 2 )SC(O)R i j

9) —(CH 2 )SC(O)NR e R j ,

10) —(CH 2 ) S NR e C(O)R j ,

11) —(CH 2 ) S NR e C(O)OR j ,

12) —(CH 2 ) S NR e C(O)N(R e ) 2 ,

13) —(CH 2 ) S NR e C(O)NR e R j ,

14) —(CH 2 ) S NR e S(O) m R j ,

15) —(CH 2 ) S NR e S(O) m N(R e ) 2 ,

16) —(CH 2 ) S NR e S(O) m NR e R j , and

17) —(CH 2 ) S NR e R j ,

wherein each CH 2 , alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from R f , and

wherein R 2 and R 3 and the carbon atom they are connected to can form a —C 3-5 cycloalkyl ring, or wherein R 2 and R 4 and the carbon atoms they are connected to can form a —C 3-5 cycloalkyl ring;

R 3 is selected from the group consisting of:

1) hydrogen,

2) —C 1-6 alkyl,

3) —C 2-6 alkenyl,

4) —C 2-6 alkynyl,

5) —C 3-10 cycloalkyl,

6) —C 2-10 cycloheteroalkyl,

7) —C 1-6 alkyl-O—C 1-6 alkyl-,

8) —(CH 2 ) S C(O)R j ,

9) —(CH 2 ) S C(O)NR e R j ,

10) —(CH 2 ) S NR e C(O)R j ,

11) —(CH 2 ) S NR e C(O)OR j ,

12) —(CH 2 ) S NR e C(O)N(R e ) 2 ,

13) —(CH 2 ) S NR e C(O)NR e R j ,

14) —(CH 2 ) S NR e S(O) m R j ,

15) —(CH 2 ) S NR e S(O) m N(R e ) 2 ,

16) —(CH 2 ) S NR e S(O) m NR e R j , and

17) —(CH 2 ) S NR e R j ,

wherein each CH 2 , alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from R g ;

R 4 is selected from the group consisting of:

1) hydrogen, and

2) —C 1-6 alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from halogen;

R 5 is selected from the group consisting of:

1) hydrogen, and

2) C 1-6 alkyl;

R 6 is selected from the group consisting of:

1) hydrogen,

2) —C 1-6 alkyl,

3) —C 2-6 alkenyl, and

4) —C 2-6 alkynyl,

wherein each alkyl, alkenyl and alkynyl is unsubstituted or substituted with one to five substituents selected from halogen;

each R a is independently selected from the group consisting of:

1) —CF 3 ,

2) —OCF 3 ,

3) —CHF 2 ,

4) —OCHF 2 ,

5) —CH 2 CF 3 ,

6) —OCH 2 CF 3 ,

7) —CF 2 CH 3 ;

8) CN,

9) oxo,

10) halogen,

11) —S(O) 2 C 1-6 alkyl,

12) —C 1-6 alkyl,

13) —C 2-6 alkenyl,

14) —C 2-6 alkynyl,

15) —C 3-6 cycloalkyl,

16) —C 2-6 cycloheteroalkyl,

17) aryl,

18) heteroaryl,

19) —C 1-6 alkyl-aryl,

20) —C 1-6 alkyl-heteroaryl,

21) —C 1-6 alkyl-C 3-6 cycloalkyl,

22) —C 1-6 alkyl-C 2-6 cycloheteroalkyl,

23) —C 2-6 alkenyl-C 3-6 cycloalkyl,

24) —C 2-6 alkenyl-C 2-6 cycloheteroalkyl,

21) —C 2-6 alkenyl-aryl,

22) —C 2-6 alkenyl-heteroaryl,

27) —C 2-6 alkynyl-C 3-6 cycloalkyl,

23) —C 2-6 alkynyl-C 2-6 cycloheteroalkyl,

24) —C 2-6 alkynyl-aryl,

25) —C 2-6 alkynyl-heteroaryl,

26) —OH,

27) —(CH 2 ) p —OC 1-6 alkyl,

28) —(CH 2 ) p —OC 2-6 alkenyl,

29) —(CH 2 ) p —OC 2-6 alkynyl,

30) —(CH 2 ) p —OC 3-6 cycloalkyl,

31) —(CH 2 ) p —OC 2-6 heterocycloalkyl,

32) —(CH 2 ) p —O-aryl,

33) —(CH 2 ) p —O-heteroaryl,

34) —OC 1-6 alkyl-C 3-6 cycloalkyl,

40) —OC 1-6 alkyl-C 2-6 heterocycloalkyl,

41) —OC 1-6 alkyl-aryl,

42) —OC 1-6 alkyl-heteroaryl,

43) —S(O) m R j ,

44) —C 1-6 alkyl-S(O) m R j ,

45) —N(R k ) 2 , and

46) —NR k R L ,

wherein each R a is unsubstituted or substituted with one to six substituents selected from halogen, CF 3 , OH, —C 1-6 alkyl, and —OC 1-6 alkyl;

each R b is independently selected from the group consisting of:

1) —CF 3 ,

2) —OCF 3 ,

3) —CHF 2 ,

4) —OCHF 2 ,

5) —CH 2 CF 3 ,

6) —OCH 2 CF 3 ,

7) —CF 2 CH 3 ;

8) CN,

9) oxo,

10) halogen,

11) —S(O) 2C 1-6 alkyl,

12) —C 1-6 alkyl,

13) —C 2-6 alkenyl,

14) —C 2-6 alkynyl,

15) —O—C 1-6 alkyl,

16) —C 3-6 cycloalkyl,

17) —O—C 3-6 cycloalkyl,

18) —C 2-6 cycloheteroalkyl,

19) aryl,

20) heteroaryl,

21) —C 1-6 alkyl-aryl,

22) —C 1-6 alkyl-heteroaryl,

23) —C 1-6 alkyl-C 3-6 cycloalkyl,

24) —C 1-6 alkyl-C 2-6 cycloheteroalkyl,

21) —C 2-6 alkenyl-C 3-6 cycloalkyl,

22) —C 2-6 alkenyl-C 2-6 cycloheteroalkyl,

27) —C 2-6 alkenyl-aryl,

23) —C 2-6 alkenyl-heteroaryl,

24) —C 2-6 alkynyl-C 3-6 cycloalkyl,

25) —C 2-6 alkynyl-C 2-6 cycloheteroalkyl,

26) —C 2-6 alkynyl-aryl,

27) —C 2-6 alkynyl-heteroaryl, 33) —OH,

28) —(CH 2 ) q —OC 1-6 alkyl,

29) —(CH 2 ) q —OC 2-6 alkenyl,

30) —(CH 2 ) q —OC 2-6 alkynyl,

31) —(CH 2 ) q —OC 3-6 cycloalkyl,

32) —(CH 2 ) q —OC 2-6 heterocycloalkyl,

33) —(CH 2 ) q —O-aryl,

34) —(CH 2 ) q —O-heteroaryl,

40) —OC 1-6 alkyl-C 3-6 cycloalkyl,

41) —OC 1-6 alkyl-C 2-6 heterocycloalkyl,

42) —OC 1-6 alkyl-aryl,

43) —OC 1-6 alkyl-heteroaryl,

44) —S(O) m R j ,

45) —C 1-6 alkyl-S(O) m R j ,

46) —C(O)R d , and

47) —NR k R L ,

wherein each R b is unsubstituted or substituted with one to six substituents selected from halogen, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , —C 1-6 alkyl, and —OC 1-6 alkyl;

R c is selected from:

1) —C 1-6 alkyl,

2) OH,

3) halogen, and

4) —OC 1-6 alkyl,

wherein alkyl can be unsubstituted or substituted with one to three halogens;

R d is selected from:

1) hydrogen,

2) C 1-6 alkyl,

3) C 3-6 cycloalkyl,

4) aryl, and

5) heteroaryl;

R e is selected from:

1) hydrogen, and

2) C 1-6 alkyl;

R f is selected from:

1) —C 1-6 alkyl,

2) OH,

3) halogen, and

4) —OC 1-6 alkyl,

wherein alkyl can be unsubstituted or substituted with one to three halogens;

R g is selected from:

1) —C 1-6 alkyl,

2) OH,

3) halogen, and

4) —OC 1-6 alkyl,

wherein alkyl can be unsubstituted or substituted with one to three halogens;

R h is selected from:

1) hydrogen, and

2) C 1-6 alkyl;

R i is selected from:

1) hydrogen,

2) C 1-6 alkyl,

3) C 3-6 cycloalkyl,

4) aryl, and

5) heteroaryl;

R j is selected from:

1) hydrogen,

2) C 1-6 alkyl,

3) C 3-6 alkenyl,

4) C 3-6 alkynyl,

5) C 3-6 cycloalkyl,

6) C 2-5 cycloheteroalkyl,

7) aryl, and

8) heteroaryl;

R k is selected from:

1) hydrogen, and

2) C 1-6 alkyl;

R L is selected from:

1) hydrogen,

2) C 1-6 alkyl,

3) C 3-6 cycloalkyl,

4) aryl, and

5) heteroaryl;

m is independently selected from 0 to 2;

n is independently selected from 2 to 6;

p is independently selected from 0 to 3;

q is independently selected from 0 to 3;

r is independently selected from 0 to 2; and

s is independently selected from 0 to 6.

2 . The compound according to claim 1 wherein A is selected from the group consisting of

1) aryl, and

2) heteroaryl,

wherein each aryl and heteroaryl is unsubstituted or substituted with one to five substituents selected from R a ; or a pharmaceutically acceptable salt thereof.

3 . The compound according to claim 1 wherein A is selected from the group consisting of:

1) phenyl, and

2) pyridine,

wherein each phenyl and pyridine is unsubstituted or substituted with one to five substituents selected from R a ; or a pharmaceutically acceptable salt thereof.

4 . The compound according to claim 1 wherein B is independently selected from the group consisting of:

1) aryl,

2) heteroaryl,

3) —C 1-6 alkyl-aryl,

4) —C 3-8 cycloalkyl-aryl,

5) —C 2-8 cycloheteroalkyl-aryl,

6) —C 1-6 alkyl-heteroaryl,

7) —C 3-8 cycloalkyl-heteroaryl,

8) —C 2-8 cycloheteroalkyl-heteroaryl,

9) —C 1-6 alkyl-O-aryl,

10) —C 1-6 alkyl-O-heteroaryl,

11) C 3-12 cycloalkyl,

12) C 2-12 cycloheteroalkyl,

13) —C 1-6 alkyl-C 3-12 cycloalkyl,

14) —C 1-6 alkyl-C 2-12 cycloheteroalkyl,

15) —C 1-6 alkyl-O—C 3-12 cycloalkyl,

16) —C 1-6 alkyl-O—C 2-12 cycloheteroalkyl,

17) —C 0-6 alkyl-aryl fused to a C 4-6 cycloalkyl or C 4-6 cycloheteroalkyl containing 1-3 heteroatoms independently selected from O, S and N(R h ) 2 ,

18) —C 0-6 alkyl-aryl fused to a C 4-6 cycloalkenyl or C 4-6 cycloheteroalkenyl containing 1-3 heteroatoms independently selected from O, S and N(R h ) 2 ,

19) —C 0-6 alkyl-heteroaryl fused to C 4-6 cycloalkyl or C 4-6 cycloheteroalkyl containing 1-3 heteroatoms independently selected from O, S and N(R h ) 2 , and

20) —C 0-6 alkyl-heteroaryl fused to C 4-6 cycloalkenyl or C 4-6 cycloheteroalkenyl containing 1-3 heteroatoms independently selected from O, S and N(R h ) 2 ,

wherein alkyl, cycloalkyl, cycloheteroalkyl, cycloalkenyl, aryl and heteroaryl are unsubstituted or substituted with one to five substituents selected from R b ;

or a pharmaceutically acceptable salt thereof.

5 . The compound according to claim 1 wherein B is independently selected from the group consisting of:

1) aryl,

2) heteroaryl,

3) —C 1-6 alkyl-aryl,

4) —C 1-6 alkyl-O-aryl,

5) —C 1-6 alkyl-O-heteroaryl,

6) C 3-12 cycloalkyl,

7) C 2-12 cycloheteroalkyl, and

8) —C 1-6 alkyl-C 3-12 cycloalkyl,

wherein alkyl, cycloalkyl, cycloheteroalkyl, aryl and heteroaryl are unsubstituted or substituted with one to five substituents selected from R b ; or a pharmaceutically acceptable salt thereof.

6 . The compound according to claim 1 wherein B is independently selected from the group consisting of:

1) phenyl,

2) naphthalene,

3) pyridine,

4) pyrazole,

5) thiazole,

6) pyrimidine,

7) pyridazine,

8) imidazole,

9) oxazole,

10) indazole,

11) thiophene,

12) —CH 2 -phenyl,

13) —(CH 2 ) 2 -phenyl,

14) —CH 2 —O-phenyl,

15) —CH 2 —O-pyridine,

16) adamantane,

17) cubane,

18) cyclopropane,

19) cyclobutane,

20) cyclopentane,

21) cyclohexane,

22) cycloheptane,

23) bicyclo[2.2.1]-heptane,

24) bicyclo[3.1.0]hexane,

25) bicyclo[1.1.1]pentane,

26) piperidine,

27) pyrrolidine,

28) tetrahydropyran, and

29) —CH 2 -cyclohexane,

wherein B is unsubstituted or substituted with one to five substituents selected from R b ;

or a pharmaceutically acceptable salt thereof.

7 . The compound according to claim 1 wherein B is independently selected from the group consisting of:

1) aryl, and

2) heteroaryl,

wherein aryl and heteroaryl are unsubstituted or substituted with one to five substituents selected from R b ; or a pharmaceutically acceptable salt thereof.

8 . The compound according to claim 1 wherein B is independently selected from the group consisting of:

1) phenyl,

2) pyridine,

3) pyrazole, and

4) thiazole,

wherein aryl and heteroaryl are unsubstituted or substituted with one to five substituents selected from R b ; or a pharmaceutically acceptable salt thereof.

9 . The compound according to claim 1 wherein R 5 is hydrogen; or a pharmaceutically acceptable salt thereof.

10 . The compound according to claim 1 wherein

R 1 is selected from the group consisting of

1) hydrogen, and

2) —C 1-6 alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R c ;

R 2 is selected from the group consisting of

1) hydrogen, and

2) —C 1-6 alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R f ;

R 3 is selected from the group consisting of

1) hydrogen, and

2) —C 1-6 alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R g ; and

R 6 is selected from the group consisting of

1) hydrogen, and

2) —C 1-6 alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from halogen; or a pharmaceutically acceptable salt thereof.

11 . The compound according to claim 1 wherein R 1 , R 2 , R 3 , R 4 , and R 6 are hydrogen; or a pharmaceutically acceptable salt thereof.

12 . The compound according to claim 1 wherein each R a is independently selected from the group consisting of:

1) —CF 3 ,

2) —OCF 3 ,

3) —CHF 2 ,

4) —OCHF 2 ,

5) —CH 2 CF 3 ,

6) —OCH 2 CF 3 ,

7) —CF 2 CH 3 ,

8) CN,

9) halogen, and

10) —C 1-6 alkyl,

wherein each R a is unsubstituted or substituted with one to six substituents selected from halogen, CF 3 , OH, —C 1-6 alkyl, and —OC 1-6 alkyl; or a pharmaceutically acceptable salt thereof.

13 . The compound according to claim 1 wherein each R a is independently selected from the group consisting of:

1) —CF 3 ,

2) —OCF 3 ,

3) CN, and

4) halogen;

or a pharmaceutically acceptable salt thereof.

14 . The compound according to claim 1 wherein each R b is independently selected from the group consisting of:

1) —CF 3 ,

2) —OCF 3 ,

3) —CHF 2 ,

4) —OCHF 2 ,

5) —CH 2 CF 3 ,

6) —OCH 2 CF 3 ,

7) CN,

8) halogen,

9) —S(O) 2 C 1-6 alkyl,

10) —C 1-6 alkyl,

11) —O—C 1-6 alkyl,

12) —C 3-6 cycloalkyl, and

13) aryl,

wherein each R b is unsubstituted or substituted with one to six substituents selected from halogen, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , —C 1-6 alkyl, and —OC 1-6 alkyl;

or a pharmaceutically acceptable salt thereof.

15 . The compound according to claim 1 wherein each R b is independently selected from the group consisting of:

1) —CF 3 ,

2) —OCH 2 CF 3 , and

3) halogen;

or a pharmaceutically acceptable salt thereof.

16 . The compound according to claim 1 wherein

A is selected from the group consisting of:

1) aryl, and

2) heteroaryl,

wherein each aryl and heteroaryl is unsubstituted or substituted with one to five substituents selected from R a ;

B is independently selected from the group consisting of:

1) aryl,

2) heteroaryl,

3) —C 1-6 alkyl-aryl,

4) —C 1-6 alkyl-O-aryl,

5) —C 1-6 alkyl-O-heteroaryl,

6) C 3-12 cycloalkyl,

7) C 2-12 cycloheteroalkyl, and

8) —C 1-6 alkyl-C 3-12 cycloalkyl,

wherein alkyl, cycloalkyl, cycloheteroalkyl, aryl and heteroaryl are unsubstituted or substituted with one to five substituents selected from R b ;

R 1 is selected from the group consisting of

1) hydrogen, and

2) —C 1-6 alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R c ;

R 2 is selected from the group consisting of

1) hydrogen, and

2) —C 1-6 alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R f ;

R 3 is selected from the group consisting of

1) hydrogen, and

2) —C 1-6 alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R g ; and

R 4 is selected from the group consisting of

1) hydrogen, and

2) —C 1-6 alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from halogen;

R 5 is hydrogen;

R 6 is selected from the group consisting of

1) hydrogen, and

2) —C 1-6 alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from halogen;

each R a is independently selected from the group consisting of:

1) —CF 3 ,

2) —OCF 3 ,

3) —CHF 2 ,

4) —OCHF 2 ,

5) —CH 2 CF 3 ,

6) —OCH 2 CF 3 ,

7) —CF 2 CH 3 ,

8) CN,

9) halogen, and

10) —C 1-6 alkyl,

wherein each R a is unsubstituted or substituted with one to six substituents selected from halogen, CF 3 , OH, —C 1-6 alkyl, and —OC 1-6 alkyl;

each R b is independently selected from the group consisting of:

1) —CF 3 ,

2) —OCF 3 ,

3) —CHF 2 ,

4) —OCHF 2 ,

5) —CH 2 CF 3 ,

6) —OCH 2 CF 3 ,

7) CN,

8) halogen,

9) —S(O) 2 C 1-6 alkyl,

10) —C 1-6 alkyl,

11) —O—C 1-6 alkyl,

12) —C 3-6 cycloalkyl, and

13) aryl,

wherein each R b is unsubstituted or substituted with one to six substituents selected from halogen, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , —C 1-6 alkyl, and —OC 1-6 alkyl;

or a pharmaceutically acceptable salt thereof.

17 . The compound according to claim 1 wherein

A is selected from the group consisting of:

1) aryl, and

2) heteroaryl,

wherein each aryl and heteroaryl is unsubstituted or substituted with one to five substituents selected from R a ;

B is independently selected from the group consisting of:

1) aryl, and

2) heteroaryl,

wherein aryl and heteroaryl are unsubstituted or substituted with one to five substituents selected from R b ;

R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are hydrogen;

each R a is independently selected from the group consisting of:

1) —CF 3 ,

2) —OCF 3 ,

3) CN, and

4) halogen;

each R b is independently selected from the group consisting of:

1) —CF 3 ,

2) —OCH 2 CF 3 , and

3) halogen;

or a pharmaceutically acceptable salt thereof.

18 . The compound according to claim 1 selected from:

1) (S)—N—((R)-(3-chloro-4-fluorophenyl)(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)-2-oxooxazolidine-5-carboxamide;

2) (S)—N—((S)-(3-chloro-4-fluorophenyl)(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)-2-oxooxazolidine-5-carboxamide;

3) (S)—N—((R)-(5-chloro-6-(trifluoromethyl)pyridin-2-yl)(4-chlorophenyl)methyl)-2-oxooxazolidine-5-carboxamide;

4) (S)—N—((S)-(5-chloro-6-(trifluoromethyl)pyridin-2-yl)(4-chlorophenyl)methyl)-2-oxooxazolidine-5-carboxamide;

5) (S)—N—((R)-bicyclo[2.2.1]heptan-1-yl(4-chlorophenyl)methyl)-2-oxooxazolidine-5-carboxamide;

6) (S)—N—((S)-bicyclo[2.2.1]heptan-1-yl(4-chlorophenyl)methyl)-2-oxooxazolidine-5-carboxamide;

7) (S)—N—((R)-(4-chlorophenyl)(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)methyl)-2-oxooxazolidine-5-carboxamide;

8) (S)—N—((S)-(4-chlorophenyl)(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)methyl)-2-oxooxazolidine-5-carboxamide;

9) (S)—N—((R)-(3-chloro-4-fluorophenyl)(5-(trifluoromethyl)-1H-pyrazol-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

10) (S)—N—((S)-(3-chloro-4-fluorophenyl)(5-(trifluoromethyl)-1H-pyrazol-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

11) (cis)-N-(bis(4-chlorophenyl)methyl)-4-methyl-2-oxooxazolidine-5-carboxamide;

12) (trans)-N-(bis(4-chlorophenyl)methyl)-4-methyl-2-oxooxazolidine-5-carboxamide;

13) (R)—N-(bis(4-chlorophenyl)methyl)-5-methyl-2-oxooxazolidine-5-carboxamide;

14) (S)—N-(bis(4-chlorophenyl)methyl)-5-methyl-2-oxooxazolidine-5-carboxamide;

15) (S)—N—((R)-2-(3-chloro-4-fluorophenoxy)-1-(3-chloro-4-fluorophenyl)ethyl)-2-oxo-oxazolidine-5-carboxamide;

16) (S)—N—((S)-2-(3-chloro-4-fluorophenoxy)-1-(3-chloro-4-fluorophenyl)ethyl)-2-oxo-oxazolidine-5-carboxamide;

17) (S)—N—((R)-(3-chloro-2,4-difluorophenyl)((2S,5R)-5-(trifluoromethyl)tetrahydro-2H-pyran-2-yl)methyl)-2-oxooxazolidine-4-carboxamide;

18) (S)—N—((R)-(3-chloro-2,4-difluorophenyl)((2R,5S)-5-(trifluoromethyl)tetrahydro-2H-pyran-2-yl)methyl)-2-oxooxazolidine-4-carboxamide;

19) (S)—N—((S)-(3-chloro-2,4-difluorophenyl)((2S,5R)-5-(trifluoromethyl)tetrahydro-2H-pyran-2-yl)methyl)-2-oxooxazolidine-4-carboxamide;

20) (S)—N—((S)-(3-chloro-2,4-difluorophenyl)((2R,5S)-5-(trifluoromethyl)tetrahydro-2H-pyran-2-yl)methyl)-2-oxooxazolidine-4-carboxamide;

21) (S)—N-(bis(3-chloro-4-fluorophenyl)methyl)-2-oxooxazolidine-5-carboxamide;

22) (S)—N—((R)-(4-chlorophenyl)(2-(trifluoromethyl)pyrimidin-4-yl)methyl)-2-oxo-oxazolidine-5-carboxamide;

23) (S)—N—((S)-(4-chlorophenyl)(2-(trifluoromethyl)pyrimidin-4-yl)methyl)-2-oxo-oxazolidine-5-carboxamide;

24) (S)—N—((R)-(4-chlorophenyl)(4-(trifluoromethyl)thiazol-2-yl)methyl)-2-oxo-oxazolidine-5-carboxamide;

25) (S)—N—((S)-(4-chlorophenyl)(4-(trifluoromethyl)thiazol-2-yl)methyl)-2-oxo-oxazolidine-5-carboxamide;

26) (S)—N—((R)-(3-chloro-4-fluorophenyl)(5-chloropyridin-3-yl)methyl)-2-oxo-oxazolidine-5-carboxamide;

27) (S)—N—((S)-(3-chloro-4-fluorophenyl)(5-chloropyridin-3-yl)methyl)-2-oxo-oxazolidine-5-carboxamide;

28) (S)—N—((R)-(4-chlorophenyl)(1H-indazol-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

29) (S)—N—((S)-(4-chlorophenyl)(1H-indazol-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

30) (S)—N—((R)-(4-chlorophenyl)(6-(difluoromethyl)-5-fluoropyridin-2-yl)methyl)-2-oxooxazolidine-5-carboxamide;

31) (S)—N—((S)-(4-chlorophenyl)(6-(difluoromethyl)-5-fluoropyridin-2-yl)methyl)-2-oxooxazolidine-5-carboxamide;

32) (S)—N—((R)-(4-chlorophenyl)(2-(trifluoromethyl)-1H-imidazol-4-yl)methyl)-2-oxo-oxazolidine-5-carboxamide;

33) (S)—N—((S)-(4-chlorophenyl)(2-(trifluoromethyl)-1H-imidazol-4-yl)methyl)-2-oxo-oxazolidine-5-carboxamide;

34) (S)—N—((R)-(4-chlorophenyl)(2-(trifluoromethyl)oxazol-4-yl)methyl)-2-oxo-oxazolidine-5-carboxamide;

35) (S)—N—((S)-(4-chlorophenyl)(2-(trifluoromethyl)oxazol-4-yl)methyl)-2-oxo-oxazolidine-5-carboxamide;

36) (S)—N—((R)-(3-chloro-4-fluorophenyl)(4-chlorophenyl)methyl)-2-oxooxazolidine-5-carboxamide;

37) (S)—N—((S)-(3-chloro-4-fluorophenyl)(4-chlorophenyl)methyl)-2-oxooxazolidine-5-carboxamide;

38) (5S)—N-((3,5-dichlorophenyl)(phenyl)methyl)-2-oxooxazolidine-5-carboxamide;

39) (5S)—N-((adamantan-2-yl)(phenyl)methyl)-2-oxooxazolidine-5-carboxamide;

40) (S)—N—((R)-(4-chlorophenyl)(6-methoxypyridin-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

41) (S)—N—((S)-(4-chlorophenyl)(6-methoxypyridin-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

42) (S)—N—((R)-(4-chlorophenyl)(5-fluoropyridin-2-yl)methyl)-2-oxooxazolidine-5-carboxamide;

43) (S)—N—((S)-(4-chlorophenyl)(5-fluoropyridin-2-yl)methyl)-2-oxooxazolidine-5-carboxamide;

44) (5S)—N-((4-chlorophenyl)(thiophen-2-yl)methyl)-2-oxooxazolidine-5-carboxamide;

45) (S)—N—((R)-(3,4-dichlorophenyl)(phenyl)methyl)-2-oxooxazolidine-5-carboxamide;

46) (S)—N—((S)-(3,4-dichlorophenyl)(phenyl)methyl)-2-oxooxazolidine-5-carboxamide;

47) (5S)—N—((R)-(3-chlorophenyl)((cis)-2-phenylcyclopropyl)methyl)-2-oxooxazolidine-5-carboxamide;

48) (5S)—N—((R)-(3-chlorophenyl)((trans)-2-phenylcyclopropyl)methyl)-2-oxooxazolidine-5-carboxamide;

49) (5S)—N—((S)-(3-chlorophenyl)((cis)-2-phenylcyclopropyl)methyl)-2-oxooxazolidine-5-carboxamide;

50) (5S)—N—((S)-(3-chlorophenyl)((trans)-2-phenylcyclopropyl)methyl)-2-oxooxazolidine-5-carboxamide;

51) (5S)—N-((4-chlorophenyl)(3-(methylsulfonyl)phenyl)methyl)-2-oxooxazolidine-5-carboxamide;

52) (S)—N—((R)-(5-chloro-2-methoxyphenyl)(3-chlorophenyl)methyl)-2-oxooxazolidine-5-carboxamide;

53) (S)—N—((S)-(5-chloro-2-methoxyphenyl)(3-chlorophenyl)methyl)-2-oxooxazolidine-5-carboxamide;

54) (S)—N—((R)-(4-chlorophenyl)(2,3-difluorophenyl)methyl)-2-oxooxazolidine-5-carboxamide;

55) (S)—N—((S)-(4-chlorophenyl)(2,3-difluorophenyl)methyl)-2-oxooxazolidine-5-carboxamide;

56) (5S)—N-((4-chlorophenyl)(naphthalen-1-yl)methyl)-2-oxooxazolidine-5-carboxamide;

57) (5S)—N-((4-chlorophenyl)(naphthalen-2-yl)methyl)-2-oxooxazolidine-5-carboxamide;

58) (S)—N—((R)-(4-chlorophenyl)(3-isopropylphenyl)methyl)-2-oxooxazolidine-5-carboxamide;

59) (S)—N—((S)-(4-chlorophenyl)(3-isopropylphenyl)methyl)-2-oxooxazolidine-5-carboxamide;

60) (S)—N—((R)-(4-chlorophenyl)(3-cyclopropylphenyl)methyl)-2-oxooxazolidine-5-carboxamide;

61) (S)—N—((S)-(4-chlorophenyl)(3-cyclopropylphenyl)methyl)-2-oxooxazolidine-5-carboxamide;

62) (5S)—N-((4-chlorophenyl)(2-(trifluoromethyl)pyridin-4-yl)methyl)-2-oxooxazolidine-5-carboxamide;

63) (S)—N—((R)-(4-chloro-3-(trifluoromethyl)phenyl)(4-chlorophenyl)methyl)-2-oxooxazolidine-5-carboxamide;

64) (S)—N—((S)-(4-chloro-3-(trifluoromethyl)phenyl)(4-chlorophenyl)methyl)-2-oxooxazolidine-5-carboxamide;

65) (5S)—N-((4-chlorophenyl)(6-(difluoromethoxy)pyridin-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

66) (S)—N—((R)-(4-chlorophenyl)(5-(trifluoromethyl)pyridin-2-yl)methyl)-2-oxo-oxazolidine-5-carboxamide;

67) (S)—N—((S)-(4-chlorophenyl)(5-(trifluoromethyl)pyridin-2-yl)methyl)-2-oxo-oxazolidine-5-carboxamide;

68) (5S)—N-((3-chloro-4-fluorophenyl)(5-fluoro-6-(trifluoromethyl)pyridin-2-yl)methyl)-2-oxooxazolidine-5-carboxamide;

69) (S)—N—((R)-(4-(tert-butyl)thiazol-2-yl)(4-chlorophenyl)methyl)-2-oxooxazolidine-5-carboxamide;

70) (S)—N—((S)-(4-(tert-butyl)thiazol-2-yl)(4-chlorophenyl)methyl)-2-oxooxazolidine-5-carboxamide;

71) (5S)—N-((4-chlorophenyl)(4-(trifluoromethyl)-1H-imidazol-2-yl)methyl)-2-oxo-oxazolidine-5-carboxamide;

72) (S)—N-(1,1-bis(4-chlorophenyl)ethyl)-2-oxooxazolidine-5-carboxamide;

73) (S)—N—((R)-(4-chlorophenyl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl)-2-oxooxazolidine-5-carboxamide;

74) (S)—N—((S)-(4-chlorophenyl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl)-2-oxo-oxazolidine-5-carboxamide;

75) (S)—N—((R)-(3-chloro-4-fluorophenyl)((R)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

76) (S)—N—((R)-(3-chloro-4-fluorophenyl)((S)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

77) (S)—N—((S)-(3-chloro-4-fluorophenyl)((R)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

78) (S)—N—((S)-(3-chloro-4-fluorophenyl)((S)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

79) (S)—N—((R)-(3-chloro-4-fluorophenyl)(2-(trifluoromethyl)thiazol-4-yl)methyl)-2-oxooxazolidine-5-carboxamide;

80) (S)—N—((S)-(3-chloro-4-fluorophenyl)(2-(trifluoromethyl)thiazol-4-yl)methyl)-2-oxooxazolidine-5-carboxamide;

81) (5S)—N-((4-chlorophenyl)(cycloheptyl)methyl)-2-oxooxazolidine-5-carboxamide;

82) (S)—N—((R)-(4-chloro-3-methylphenyl)(4-chlorophenyl)methyl)-2-oxooxazolidine-5-carboxamide;

83) (S)—N—((S)-(4-chloro-3-methylphenyl)(4-chlorophenyl)methyl)-2-oxooxazolidine-5-carboxamide;

84) (S)—N—((R)-(4-chloro-2-(trifluoromethoxy)phenyl)(4-chlorophenyl)methyl)-2-oxooxazolidine-5-carboxamide;

85) (S)—N—((S)-(4-chloro-2-(trifluoromethoxy)phenyl)(4-chlorophenyl)methyl)-2-oxo-oxazolidine-5-carboxamide;

86) (S)—N—((R)-(3-chloro-4-fluorophenyl)(4-(difluoromethoxy)phenyl)methyl)-2-oxo-oxazolidine-5-carboxamide;

87) (S)—N—((S)-(3-chloro-4-fluorophenyl)(4-(difluoromethoxy)phenyl)methyl)-2-oxo-oxazolidine-5-carboxamide;

88) (S)—N—((R)-(3-chloro-4-fluorophenyl)(6-(trifluoromethyl)pyridin-2-yl)methyl)-2-oxooxazolidine-5-carboxamide;

89) (S)—N—((S)-(3-chloro-4-fluorophenyl)(6-(trifluoromethyl)pyridin-2-yl)methyl)-2-oxooxazolidine-5-carboxamide;

90) (S)—N—((R)-(3-chloro-2,4-difluorophenyl)(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

91) (S)—N—((S)-(3-chloro-2,4-difluorophenyl)(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

92) (S)—N—((R)-(3-chloro-4-(trifluoro-methoxy)phenyl)(2-(trifluoromethyl)oxazol-4-yl)methyl)-2-oxooxazolidine-5-carboxamide;

93) (S)—N—((S)-(3-chloro-4-(trifluoro-methoxy)phenyl)(2-(trifluoromethyl)oxazol-4-yl)methyl)-2-oxooxazolidine-5-carboxamide;

94) (S)—N—((R)-(3-chloro-4-(trifluoromethoxy)phenyl)(2-(trifluoro-methyl)pyrimidin-4-yl)methyl)-2-oxooxazolidine-5-carboxamide;

95) (S)—N—((S)-(3-chloro-4-(trifluoromethoxy)phenyl)(2-(trifluoro-methyl)pyrimidin-4-yl)methyl)-2-oxooxazolidine-5-carboxamide;

96) (S)—N—((R)-(3-chloro-4-(trifluoro-methoxy)phenyl)(1-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)-2-oxooxazolidine-5-carboxamide;

97) (S)—N—((S)-(3-chloro-4-(trifluoro-methoxy)phenyl)(1-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)-2-oxooxazolidine-5-carboxamide;

98) (S)—N—((R)-(3-chloro-4-cyano-phenyl)(5-chloro-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

99) (S)—N—((S)-(3-chloro-4-cyano-phenyl)(5-chloro-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

100) (S)—N—((R)-(4-chloro-2-methoxyphenyl)(4-fluorophenyl)methyl)-2-oxooxazolidine-5-carboxamide;

101) (S)—N—((S)-(4-chloro-2-methoxyphenyl)(4-fluorophenyl)methyl)-2-oxooxazolidine-5-carboxamide;

102) (S)—N—((R)-(4-chlorophenyl)(cuban-1-yl)methyl)-2-oxooxazolidine-5-carboxamide;

103) (S)—N—((S)-(4-chlorophenyl)(cuban-1-yl)methyl)-2-oxooxazolidine-5-carboxamide;

104) (S)—N—((R)-(4-chlorophenyl)((R)-3,3-difluorocyclopentyl)methyl)-2-oxo-oxazolidine-5-carboxamide;

105) (S)—N—((R)-(4-chlorophenyl)((S)-3,3-difluorocyclopentyl)methyl)-2-oxo-oxazolidine-5-carboxamide;

106) (S)—N—((S)-(4-chlorophenyl)((R)-3,3-difluorocyclopentyl)methyl)-2-oxo-oxazolidine-5-carboxamide;

107) (S)—N—((S)-(4-chlorophenyl)((S)-3,3-difluorocyclopentyl)methyl)-2-oxo-oxazolidine-5-carboxamide;

108) (S)—N—((R)-(3-chloro-4-fluorophenyl)(2-methoxypyridin-3-yl)methyl)-2-oxo-oxazolidine-5-carboxamide;

109) (S)—N—((S)-(3-chloro-4-fluorophenyl)(2-methoxypyridin-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

110) (S)—N—((R)-(3-chloro-4-fluorophenyl)(1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl)-2-oxooxazolidine-5-carboxamide;

111) (S)—N—((S)-(3-chloro-4-fluorophenyl)(1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl)-2-oxooxazolidine-5-carboxamide;

112) (S)—N—((R)-(3-chloro-4-fluorophenyl)(1-(difluoromethyl)-1H-pyrazol-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

113) (S)—N—((S)-(3-chloro-4-fluorophenyl)(1-(difluoromethyl)-1H-pyrazol-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

114) (S)—N—((R)-(3-chloro-4-fluorophenyl)(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)methyl)-2-oxooxazolidine-5-carboxamide;

115) (S)—N—((S)-(3-chloro-4-fluorophenyl)(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)methyl)-2-oxooxazolidine-5-carboxamide;

116) (S)—N—((R)-(3-chloro-4-fluorophenyl)(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

117) (S)—N—((S)-(3-chloro-4-fluorophenyl)(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

118) (S)—N—((R)-(5-chloro-6-(trifluoromethyl)pyridin-2-yl)(4,4-difluoro-cyclohexyl)-methyl)-2-oxooxazolidine-5-carboxamide;

119) (S)—N—((S)-(5-chloro-6-(trifluoromethyl)pyridin-2-yl)(4,4-difluoro-cyclohexyl)-methyl)-2-oxooxazolidine-5-carboxamide;

120) (5S)-2-oxo-N-((6-(trifluoromethyl)pyridin-3-yl)(2-(trifluoromethyl)thiazol-4-yl)methyl)-oxazolidine-5-carboxamide;

121) (S)—N—((R)-1-(3-chloro-2,4-difluorophenyl)-3-(4-chlorophenyl)propyl)-2-oxooxazolidine-5-carboxamide;

122) (S)—N—((S)-1-(3-chloro-2,4-difluorophenyl)-3-(4-chlorophenyl)propyl)-2-oxooxazolidine-5-carboxamide;

123) (5S)—N-(1-(3-chloro-4-fluorophenyl)-2-((6-(trifluoromethyl)pyridin-3-yl)oxy)ethyl)-2-oxooxazolidine-5-carboxamide;

124) (S)—N-(1-(3-chloro-2,4-difluorophenyl)-2-cyclohexylmethyl)-2-oxooxazolidine-5-carboxamide;

125) (5S)—N-(2-(4-chlorophenyl)-1-(4-(trifluoromethoxy)phenyl)ethyl)-2-oxooxazolidine-5-carboxamide;

126) (S)—N—((R)-(3-chloro-4-fluorophenyl)(3-cyano-4-fluorophenyl)methyl)-2-oxo-oxazolidine-5-carboxamide;

127) (S)—N—((S)-(3-chloro-2,4-difluorophenyl)((trans)-3-(trifluoromethyl)-cyclobutyl)-methyl)-2-oxooxazolidine-5-carboxamide;

128) (S)—N—((R)-(3-chloro-2,4-difluorophenyl)(2-(2,2,2-trifluoroethoxy)thiazol-5-yl)methyl)-2-oxooxazolidine-5-carboxamide;

129) (S)—N—((S)-(3-chloro-2,4-difluorophenyl)(2-(2,2,2-trifluoroethoxy)thiazol-5-yl)methyl)-2-oxooxazolidine-5-carboxamide;

130) (S)—N—((R)-(3-chloro-4-fluorophenyl)((trans)-4-(trifluoromethyl)cyclohexyl)methyl)-2-oxooxazolidine-5-carboxamide;

131) (S)—N—((S)-(3-chloro-4-fluorophenyl)((trans)-4-(trifluoromethyl)cyclohexyl)methyl)-2-oxooxazolidine-5-carboxamide;

132) (S)—N—((R)-(4-chlorophenyl)(6-(2,2,2-trifluoroethoxy)pyridazin-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

133) (S)—N—((S)-(4-chlorophenyl)(6-(2,2,2-trifluoroethoxy)pyridazin-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

134) (S)—N—((R)-(3-chloro-2,4-difluorophenyl)((trans)-6,6-difluorobicyclo[3.1.0]hexan-3-yl)methyl)-2-oxooxazolidine-5-carboxamide; and

135) (S)—N—((S)-(3-chloro-2,4-difluorophenyl)((trans)-6,6-difluorobicyclo[3.1.0]hexan-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

or a pharmaceutically acceptable salt thereof.

19 . The compound according to claim 1 selected from:

1) (S)—N—((R)-(3-chloro-4-fluorophenyl)(5-(trifluoromethyl)-1H-pyrazol-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

2) (S)—N—((S)-(3-chloro-4-fluorophenyl)(5-(trifluoromethyl)-1H-pyrazol-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

3) (S)—N—((R)-(3-chloro-4-fluorophenyl)(4-chlorophenyl)methyl)-2-oxooxazolidine-5-carboxamide;

4) (S)—N—((S)-(3-chloro-4-fluorophenyl)(4-chlorophenyl)methyl)-2-oxooxazolidine-5-carboxamide;

5) (S)—N—((R)-(3-chloro-4-fluorophenyl)(2-(trifluoromethyl)thiazol-4-yl)methyl)-2-oxo-oxazolidine-5-carboxamide;

6) (S)—N—((S)-(3-chloro-4-fluorophenyl)(2-(trifluoromethyl)thiazol-4-yl)methyl)-2-oxooxazolidine-5-carboxamide;

7) (S)—N—((R)-(3-chloro-2,4-difluorophenyl)(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

8) (S)—N—((S)-(3-chloro-2,4-difluorophenyl)(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methyl)-2-oxooxazolidine-5-carboxamide;

9) (S)—N—((R)-(3-chloro-2,4-difluorophenyl)((trans)-3-(trifluoromethyl)-cyclobutyl)-methyl)-2-oxooxazolidine-5-carboxamide; and

10) (S)—N—((S)-(3-chloro-2,4-difluorophenyl)((trans)-3-(trifluoromethyl)-cyclobutyl)-methyl)-2-oxooxazolidine-5-carboxamide;

or a pharmaceutically acceptable salt thereof.

20 . A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

21 . A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, for use in therapy.

22 . A method of treating a disorder, condition or disease that is responsive to the inhibition of Na v 1.8 channel activity in a patient in need thereof comprising administration of a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein the disorder is selected from:

pain disorder, a cough disorder, an acute itch disorder or chronic itch disorder.

23 . The method of claim 22 wherein the disorder is a pain disorder.

24 . The method of claim 23 , wherein the pain disorder is selected from: acute pain, inflammatory pain, or neuropathic pain.

25 . The compound according to claim 1 which is: (S)—N—((R)-(3-chloro-4-fluorophenyl)(5-(trifluoromethyl)-1H-pyrazol-3-yl)methyl)-2-oxooxazolidine-5-carboxamide; or a pharmaceutically acceptable salt thereof.

26 . The compound according to claim 1 which is: (S)—N—((S)-(3-chloro-4-fluorophenyl)(5-(trifluoromethyl)-1H-pyrazol-3-yl)methyl)-2-oxooxazolidine-5-carboxamide; or a pharmaceutically acceptable salt thereof.

27 . The compound according to claim 1 which is: (S)—N—((R)-(3-chloro-4-fluorophenyl)(4-chlorophenyl)methyl)-2-oxooxazolidine-5-carboxamide; or a pharmaceutically acceptable salt thereof.

28 . The compound according to claim 1 which is: (S)—N—((S)-(3-chloro-4-fluorophenyl)(4-chlorophenyl)methyl)-2-oxooxazolidine-5-carboxamide; or a pharmaceutically acceptable salt thereof.

29 . The compound according to claim 1 which is: (S)—N—((R)-(3-chloro-4-fluorophenyl)(2-(trifluoromethyl)thiazol-4-yl)methyl)-2-oxo-oxazolidine-5-carboxamide; or a pharmaceutically acceptable salt thereof.

30 . The compound according to claim 1 which is: (S)—N—((S)-(3-chloro-4-fluorophenyl)(2-(trifluoromethyl)thiazol-4-yl)methyl)-2-oxooxazolidine-5-carboxamide; or a pharmaceutically acceptable salt thereof.

31 . The compound according to claim 1 which is: (S)—N—((R)-(3-chloro-2,4-difluorophenyl)(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methyl)-2-oxooxazolidine-5-carboxamide; or a pharmaceutically acceptable salt thereof.

32 . The compound according to claim 1 which is: (S)—N—((S)-(3-chloro-2,4-difluorophenyl)(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methyl)-2-oxooxazolidine-5-carboxamide; or a pharmaceutically acceptable salt thereof.

33 . The compound according to claim 1 which is: (S)—N—((R)-(3-chloro-2,4-difluorophenyl)((trans)-3-(trifluoromethyl)-cyclobutyl)-methyl)-2-oxooxazolidine-5-carboxamide; or a pharmaceutically acceptable salt thereof.

34 . The compound according to claim 1 which is: (S)—N—((S)-(3-chloro-2,4-difluorophenyl)((trans)-3-(trifluoromethyl)-cyclobutyl)-methyl)-2-oxooxazolidine-5-carboxamide; or a pharmaceutically acceptable salt thereof.

Assignments (2)

MERGER Recorded Dec 9, 2022

From: MERCK SHARP & DOHME CORP.

To: MERCK SHARP & DOHME LLC

Reel/Frame 062036/0649 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2022

From: ARASAPPAN, ASHOK; BELL, IAN M.; BUNGARD, CHRISTOPHER JAMES; BURGEY, CHRISTOPHER S.; COX, JASON M.; GUIADEEN, DEODIAL GUY; KELLY, MICHAEL J., III; LAYTON, MARK E.; LIU, HONG; LIU, JIAN; OLSEN, JAMES T.; PERKINS, JAMES J.; SCHUBERT, JEFFREY W.; SHAH, AKSHAY A.; STACHEL, SHAWN J.; VANHEYST, MICHAEL DAVID; WU, ZHE

To: MERCK SHARP & DOHME CORP.

Reel/Frame 062103/0790 →

Continuity (2)

Provisional Application 63040463 · Jun 17, 2020

Related Publication 20230227441A1 · Jul 20, 2023

References Cited (100)

US 8519137B2 · Joshi et al. · 2013 [cited by applicant]

US 8629149B2 · Pajouhesh et al. · 2014 [cited by applicant]

US 9051270B2 · Hadida-Ruah et al. · 2015 [cited by applicant]

US 9108903B2 · Hadida-Ruah et al. · 2015 [cited by applicant]

US 9163042B2 · Anderson et al. · 2015 [cited by applicant]

US 9783501B2 · Hadida-Ruah et al. · 2017 [cited by applicant]

US 20120220605A1 · Pajouhesh et al. · 2012 [cited by applicant]

US 20210403457A1 · Arasappan et al. · 2021 [cited by applicant]

CN 103906733A · 2014 [cited by applicant]

EA 004988B1 · 2004 [cited by applicant]

EP 3470404A1 · 2019 [cited by applicant]

JP 2023524167A · 2023 [cited by applicant]

JP 2023530320A · 2023 [cited by applicant]

WO 2000038680A1 · 2000 [cited by applicant]

WO 2001044230A1 · 2001 [cited by applicant]

WO 2007007057A1 · 2007 [cited by applicant]

WO 2009049180A2 · 2009 [cited by applicant]

WO 2009049181A1 · 2009 [cited by applicant]

WO 2009049183A1 · 2009 [cited by applicant]

WO 2011026240A1 · 2011 [cited by applicant]

WO 2012177893A2 · 2012 [cited by applicant]

WO 2014120808A1 · 2014 [cited by applicant]

WO 2014120815A1 · 2014 [cited by applicant]

WO 2014120820A1 · 2014 [cited by applicant]

WO 2014146111A2 · 2014 [cited by applicant]

WO 2015010065A1 · 2015 [cited by applicant]

WO 2015089361A1 · 2015 [cited by applicant]

WO 2017209322A1 · 2017 [cited by applicant]

WO 2018213426A1 · 2018 [cited by applicant]

WO 2019014352A1 · 2019 [cited by applicant]

WO 2020092667A1 · 2020 [cited by applicant]

WO WO2020092667 · 2020 [cited by examiner]

WO 2020229768A1 · 2020 [cited by applicant]

WO 2021257420A1 · 2021 [cited by applicant]

De Vita, Elena et al., Synthesis and Structure-Activity Relationships of N-(4-Benzamidino)-Oxazolidinones: Potent and Selective Inhibitors of Kallikrein-Related Peptidase 6, ChemMedChem, 15, 79-95, 2020. [cited by applicant]

Piszel, Paige E. et al., Oxidative Amide Coupling from Functionally Diverse Alcohols and Amines Using Aerobic Copper/Nitroxyl Catalysis, Angew. Chem. Int. Ed., 58, 12211-12215, 2019. [cited by applicant]

Bastin, R.J.; et al., Salt Selection and Optimization Procedures for Pharmaceutical New Chemical Entities, Organic Process Research and Development, 4, pp. 427-435, 2000. [cited by applicant]

Belikov VG Pharmaceutical chemistry. Textbook. Edition Fourth. M.: “MEDpress-inform”, 2007, 622 p. (p. 11). [cited by applicant]

Belikov, V.G., Pharmaceutical Chemistry, Moscow MEDpress-inform, 4th Edition, 27-29, 2007. [cited by applicant]

Belikov, V.G., Pharmaceutical chemistry. Textbook, Moscow: MEDpress-inform, 4th Edition, 11 (2 pages), 2007. [cited by applicant]

Fundamentals of Medical Prevention. Educational and Methodological Manual for Students and Cadets of Advanced Training Cycles of State Professional Educationalinstitutions. Novosibirsk, 2016, UDC 614.2-084, BBK 51.1(2)2… [cited by applicant]

Fundamentals of Medical Prevention. Educational and Methodological Manual for Students and Cadets of Advanced Training Cycles of State Professional Educational Institutions. Novosibirsk, 2016, UDC 614.2-084, BBK 51.1(2)… [cited by applicant]

Gavrilov A.S. Pharmaceutical technology. Producing the medicines. Textbook. M.: publishing group “GEOTAR-Media”, 2010, 624 pp. (p. 20). [cited by applicant]

Gavrilov, A.S., Pharmaceutical technology. Manufacturing of medicinal products. Textbook, M.: publishing group, GEOTAR-Media, N/A, 20, 2010. [cited by applicant]

Kearns, Gregory L. et al., Developmental Pharmacology—Drug Disposition, Action, and Therapy in Infants and Children, N Engl J Med, 349, 1157-1167, 2003. [cited by applicant]

Kholodov, L.E. et al., Clinical Pharmacokinetics, Moscow, Medicine, N/A, 83-98, 134-138, 160, 378-380, 1985. [cited by applicant]

Kummerer, K., Pharmaceuticals in the environment, Annual Review of Environment and Resources, 35, 57-75, 2010. [cited by applicant]

PubChem CID: 131927238, create date Dec. 20, 2017, found [online], 7 pages. [cited by applicant]

PubChem CID: 17081319, create date Nov. 13, 2007, found [online], 7 pages. [cited by applicant]

Sergeev, P.V., Brief Course in Molecular Pharmacology, Moscow, N/A, 10, 1975. [cited by applicant]

Sergeeva, P.V. (Sergeev, P.V.), A short course in molecular pharmacology, Mockba, N/A, 10, 1975. [cited by applicant]

Bagal, Sharan K. et al., Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain, ACS Med. Chem. Lett., 2015, 650-654, 6. [cited by applicant]

Baker et al., Involvement of Na + Channels in Pain Pathways, TRENDS in Pharmacological Sciences, 2001, 27-31, 22, No. 1. [cited by applicant]

Belkouch, Mounir et al., Functional up-regulation of Nav1.8 sodium channel in AB afferent fibers subjected to chronic peripheral inflammation, Journal of Neuroinflammation, 2014, 1-17, 11:45. [cited by applicant]

Bennett, David L. et al., Painful and painless channelopathies, Lancet Neurol., 2014, 587-599, 13(6). [cited by applicant]

Black, Joel A. et a., Multiple Sodium Channel Isoforms and Mitogen-Activated Protein Kinases Are Present in Painful Human Neuromas, Ann Neurol, 2008, 644-653, 64(6). [cited by applicant]

Black, Joel A. et al., Sensory neuron-specific sodium channel SNS is abnormally expressed in the brains of mice with experimental allergic encephalomyelitis and humans with multiple sclerosis, Proc. Natl. Acad. Sci. USA… [cited by applicant]

Carter et al., Advances in the Management of Neuropathic Pain, Physical Medicine and Rehabilitation Clinics of North America, 2001, 447-459, 12(2). [cited by applicant]

Catterall, William A. et al., The chemical basis for electrical signaling, Nature Chemical Biology, 2017, 455-463, 13(5). [cited by applicant]

Colloca, Luana et al., Neuropathic pain, Nature Reviews Disease Primers, 2017, 1-19, 3:17002. [cited by applicant]

Coward, K et al., Immunolocalization of SNS/PN3 and NaN/SNS2 sodium channels in human pain states, Pain, 2000, 41-50, 85. [cited by applicant]

Denis, A. et al., 5-Aryl-β,γ butenolide, a new class of antibacterial derived from the N-aryl oxazolidinone DUP 721, Bioorganic & Medicinal Chemistry Letters, 1994, 1925-1930, 4 (16). [cited by applicant]

Emery, Edward C. et al., Novel SCN9A Mutations Underlying Extreme Pain Phenotypes: Unexpected Electrophysiological and Clinical Phenotype Correlations, Journal of Neuroscience, 2015, 7674-7681, 35(20). [cited by applicant]

Flaxman et al., Years Lived with Disability (YLDs) for 1160 Sequelae of 289 Diseases and Injuries 1990-2010: A Systematic Analysis for the Global Burden of Disease Study 2010, Lancet, 2012, 2163-2196, 380. [cited by applicant]

Goldin et al., Nomenclature of Voltage-Gated Sodium Channels, Neuron, 2000, 365-368, 28. [cited by applicant]

Goldin, Diveristy of Mammalian Voltage-Gated Sodium Channels, Ann NY Acad Sci., 1999, 38-50, 30, 868. [cited by applicant]

Han, Chongyang et al., The G1662S NaV1.8 mutation in small fibre neuropathy: impaired inactivation underlying DRG neuron hyperexcitability, J Neurol Neurosurg Psychiatry, 2014, 499-505, 85(5). [cited by applicant]

Han, Chongyang, et al., Sodium channel Nav1.8, Emerging links to human disease, Neurology, 2016, 473-483, 86. [cited by applicant]

Higuchi et al (Eds.), Pro Drugs as Novel Delivery Systems, ACS Symposium Series, 1975, 14. [cited by applicant]

Huang, Jianying et al., Small-Fiber Neuropathy Nav1.8 Mutation Shifts Activation to Hyperpolarized Potentials and Increases Excitability of Dorsal Root Ganglion Neurons, Journal of Neuroscience, 2013, 14087-14097, 33(35… [cited by applicant]

Ikoma et al., The Neurobiology of Itch, Nature Reviews, 2006, 535-547, 7. [cited by applicant]

Jarvis, Michael F. et al., A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat, PNAS, 2007, 8520-8525, 104. [cited by applicant]

Kist, Andreas M. et al., SCN10A Mutation in a Patient with Erythromelalgia Enhances C-Fiber Activity Dependent Slowing, PLOS One, 2016, pp. 1-19, 11(9):e0161789. [cited by applicant]

Kort, Michael E. et al., Discovery and Biological Evaluation of 5-Aryl-2-furfuramides, Potent and Selective Blockers of the Nav1.8 Sodium Channel with Efficacy in Models of Neuropathic and Inflammatory Pain, J. Med. Che… [cited by applicant]

Liu, Yang et al., VGLUT2-Dependent Glutamate Release from Nociceptors Is Required to Sense Pain and Suppress Itch, Neuron, 2010, 543-556, 68(3). [cited by applicant]

Luo, Jialie et al., Molecular and cellular mechanisms that initiate pain and itch, Cellular and Molecular Life Sciences, 2015, 3201-3223, 72. [cited by applicant]

Mcgaraughty, Steve et al., A Selective Nav1.8 Sodium Channel Blocker, A-803467 [5-(4-Chlorophenyl-N-(3,5-dimethoxyphenyl)furan-2-carboxamide], Attenuates Spinal Neuronal Activity in Neuropathic Rats, JPET, 2008, 1204-12… [cited by applicant]

Mcmahon et al., Itching for an Explanation, Trends Neuroscience, 1992, 497-501, 15. [cited by applicant]

Nair, Parameswaran et al., Airway Hyperresponsiveness in Asthma: Measurement and Clinical Relevance, J Allergy Clin Immunol Pract, 2017, 649-659, 5(3). [cited by applicant]

Payne, Claire Elizabeth et al., A novel selective and orally bioavailable NAv1.8 channel blocker, PF-01247324, attenuates nociception and sensory neuron excitability, British Journal of Pharmacology, 2015, 2654-2670, 17… [cited by applicant]

PubChem-SID-105546804, Modify Date: May 30, 2019 (May 30, 2019), p. 2, figure, this is a purchasable chemical, 7 pages. [cited by applicant]

PubChem-SID-350048168, Modify Date: Dec. 20, 2017 (Dec. 20, 2017), p. 2, figure, this is a purchasable chemical, 5 pages. [cited by applicant]

Riol-Blanco, Lorena et al., Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin Inflammation, Nature, 2014, 157-161, 510. [cited by applicant]

Roche, E.B., Bioreversible Carriers in Drug Design, Theory and Application, Pergamon Press, 1987. [cited by applicant]

Roostaei, Tina et al., Channelopathy-related SCN10A gene variants predict cerebellar dysfunction in multiple sclerosis, Neurology, 2016, 410-417, 86(5). [cited by applicant]

Schmelz et al., Specific C-Receptors for Itch in Human Skin, J. of Neuroscience, 1997, 8003-8008, 17(20). [cited by applicant]

Schreiber, Anne K. et al., Diabetic neuropathic pain: Physiopathology and treatment, World Journal of Diabetes, 2015, 432-444, 6(3). [cited by applicant]

Shields, Shannon D. et al., A Channelopathy Contributes to Cerebellar Dysfunction in a Model of Multiple Sclerosis, Ann Neurol, 2012, 186-194, 71(2). [cited by applicant]

Shields, Shannon D. et al., Oral Administration of PF-01247324, a Subtype-Selective Nav1.8 Blocker, Reverses Cerebellar Deficits in a Mouse Model of Multiple Sclerosis, PLoS One, 2015, 1-8, 10(3). [cited by applicant]

Talbot, Sebastien et al., Silencing Nociceptor Neurons Reduces Allergic Airway Inflammation, Neuron, 2015, 341-354, 87(2). [cited by applicant]

Van Loey et al., Itching Following Burns: Epidemiology and Predictors, British J. Dermatology, 2008, 95-100, 158. [cited by applicant]

Wood, John N et al., Voltage-gated sodium channels, Current Opinion in Pharmacolgoy, 2001, 17-21, 1. [cited by applicant]

Yiangou, Y. et al., SNS/PN3 and SNS2/NaN sodium channel-like immunoreactivity in human adult and neonate injured sensory nerves, FEBS Letters, 2000, 249-252, 467. [cited by applicant]

Yu et al., Overview of the Voltage-Gated Sodium Channel Family, Genome Biology, 2003, 207, 4. [cited by applicant]

Zeng, Chao et al., Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studie… [cited by applicant]

Zhang, Xu-Feng et al., A-887826 is a structurally novel, potent and voltage-dependent Nav1.8 sodium channel blocker that attenuates neuropathic tactile allodynia in rats, Neuropharmacology, 2010, 201-207, 59. [cited by applicant]

Zhou, Yuan et al., The Natural Flavonoid Naringenin Elicits Analgesia through Inhibition of NaV1.8 Voltage-Gated Sodium Channels, ACS Chemical Neuroscience, 2019, 4834-4846, 10. [cited by applicant]

Belikov, Relationship Between Molecular Structure of Substances and Their Effect on an Organism, Pharmaceutical chemistry, 1, pp. 43-47, 1993, RU. [cited by applicant]

Belikov, V.G., Relationship Between Molecular Structure of Substances and Their Effect on an Organism, Pharmaceutical Chemistry, Moscow, High School, 1, 43-47, 1993. [cited by applicant]

Dyson, G. and May, P., Chemistry of Synthetic Medicinal Substances, M: World, N/A, 12-19, 1964. [cited by applicant]